51. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
- Author
-
Andrea Gombos, Audrey Mailliez, Ellen Warner, Janice M. Walshe, Christobel Saunders, Manuel Ruiz Borrego, Monica Ruggeri, Karen L. Smith, Aron Goldhirsch, Larissa A. Korde, Jeong Eon Lee, Virginia F. Borges, Judith R. Kroep, Christine Rousset-Jablonski, Anna Barbro Sætersdal, Vesna Bjelic-Radisic, Hatem A. Azim, Fedro A. Peccatori, Samuel M. Niman, Junko Takei, Olivia Pagani, Akemi Kataoka, Richard D. Gelber, Ann H. Partridge, Fatima Cardoso, Cristina Saura, Marco Colleoni, Martine Piccart, Simona Borštnar, Halle C. F. Moore, Snezana Susnjar, Frédéric Amant, Chikako Shimizu, Obstetrics and Gynaecology, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, Institut Català de la Salut, [Partridge AH] Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. [Niman SM] International Breast Cancer Study Group Statistical Center, Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA. [Ruggeri M] International Breast Cancer Study Group, Program for Young Patients, Coordinating Center, Bern, 3008, Switzerland. [Peccatori FA] Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, 20141, Italy. [Azim HA] Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, 66278, Mexico. [Colleoni M] International Breast Cancer Study Group, Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
personas::sobrevivientes::supervivientes de cáncer [DENOMINACIONES DE GRUPOS] ,medicine.medical_treatment ,Embaràs ,Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproduction::Pregnancy [PHENOMENA AND PROCESSES] ,Breastfeeding ,THERAPY ,fenómenos fisiológicos reproductivos y urinarios::fenómenos fisiológicos de la reproducción::reproducción::embarazo [FENÓMENOS Y PROCESOS] ,Breast cancer ,Mama - Càncer ,Cancer Survivors ,DE-ESCALATION ,Pregnancy ,Breast-conserving surgery ,ASSAY ,Fertility preservation ,Other subheadings::/therapeutic use [Other subheadings] ,hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas [COMPUESTOS QUÍMICOS Y DROGAS] ,TREATMENT DECISIONS ,RC254-282 ,Mastectomy ,media_common ,ISSUES ,Persons::Survivors::Cancer Survivors [NAMED GROUPS] ,Obstetrics ,Obstetrics & Gynecology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones [CHEMICALS AND DRUGS] ,Oncology ,Chemotherapy, Adjuvant ,Original Article ,Female ,Pregnancy desire ,Life Sciences & Biomedicine ,medicine.drug ,Endocrine therapy ,Adult ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,media_common.quotation_subject ,Fertility ,Breast Neoplasms ,Treatment interruption ,medicine ,FERTILITY ,Humans ,ATTITUDES ,Chirurgie ,Science & Technology ,business.industry ,Otros calificadores::/uso terapéutico [Otros calificadores] ,Premenopausal women ,medicine.disease ,Hormones ,Tamoxifen ,Premenopause ,Surgery ,Young women ,business ,Hormonoteràpia - Abstract
Background: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5–10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of temporary ET interruption to allow pregnancy. Methods: POSITIVE enrolled women with stage I-III HR + early breast cancer, ≤42 years, who had received 18–30 months of adjuvant ET and wished to interrupt ET for pregnancy. Treatment interruption for up to 2 years was permitted to allow pregnancy, delivery and breastfeeding, followed by ET resumption to complete the planned duration. Findings: From 12/2014 to 12/2019, 518 women were enrolled at 116 institutions/20 countries/4 continents. At enrolment, the median age was 37 years and 74.9 % were nulliparous. Fertility preservation was used by 51.5 % of women. 93.2 % of patients had stage I/II disease, 66.0 % were node-negative, 54.7 % had breast conserving surgery, 61.9 % had received neo/adjuvant chemotherapy. Tamoxifen alone was the most prescribed ET (41.8 %), followed by tamoxifen + ovarian function suppression (OFS) (35.4 %). A greater proportion of North American women were, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2021